

**PRESS RELEASE**  
**FOOD AND DRUGS BOARD ORDERS**  
**PRODUCT RECALL**

As part of the Food and Drugs Board's (FDB) mandate to assure the quality of medicines on the Ghanaian market and to protect the public health and safety, the FDB through its post market surveillance activities has ordered the withdrawal of the following under listed batches of anti-malaria medicines from the Ghanaian Market due to quality defects.

<b>NO.</b>	<b>PRODUCT NAME</b>	<b>BATCH NUMBER</b>
1	ARTRINE TABLET	370402
2	MALAR-2 FORTE TABLETS	0101H
3	DANMETHER TABLETS	0803010
4	LUMETHER ADULT TABLETS	003
5	AREXEL TABLETS	005
6	LONART FORTE TABLETS	LF-12
7	GSUNATE 24 KIT	KF-03
8	GSUNATE 24 KIT	GO-02
9	GSUNATE 100 KIT	GO-01
10	AMONATE 400	7005
11	CAMOSUNATE PLUS ADULT TABLETS	704019
12	AMONATE-400	001
13.	PALIDAR TABLETS	051M02792
14	MALAFAN TABLETS	007
15	MALAFAN TABLETS	005
16	MALADOXINE TABLETS	MD/92027
17	MALARID TABLETS	7007
18	DANOXINE TABLETS	0705022
19	SP-DOX TABLETS	SP-04
20	SP-DOX TABLETS	SP-01
21	DAMARICH TABLETS	ME 18-342
22	MALAREICH TABLETS	470255

The Food and Drugs Board wishes to assure the general public that the FDB will continue with its post market surveillance activities to assure the quality of all medicines and other related regulated products on the Ghanaian Market. The CEO, however, warned that if the defective drugs were not withdrawn as ordered by the FDB, those companies concerned would face very stringent measures.

The Food and Drugs Board does not envisage that this recall will lead to the shortage of anti-malarial medicines on the market.

**Signed**

**Dr. Stephen K. Opuni**  
**Chief Executive Officer**